NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Asia, the Middle East, Mexico, and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989
Debt
Debt-to-Equity RatioN/A
Current Ratio2.53
Quick Ratio2.08
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.09 million
Price / Sales0.55
Cash FlowN/A
Price / CashN/A
Book Value$1.85 per share
Price / Book0.69
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-12,850,000.00
Net Margins-27.12%
Return on Equity-85.54%
Return on Assets-47.65%
Miscellaneous
Employees41
Outstanding Shares7,360,000
Market Cap$9.34
Neurometrix (NASDAQ:NURO) Frequently Asked Questions
What is Neurometrix's stock symbol?
Neurometrix trades on the NASDAQ under the ticker symbol "NURO."
When did Neurometrix's stock split? How did Neurometrix's stock split work?
Neurometrix shares reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.
How were Neurometrix's earnings last quarter?
Neurometrix Inc (NASDAQ:NURO) released its earnings results on Thursday, July, 19th. The medical device company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.39. The medical device company had revenue of $3.75 million for the quarter. Neurometrix had a negative net margin of 27.12% and a negative return on equity of 85.54%. View Neurometrix's Earnings History.
What price target have analysts set for NURO?
1 equities research analysts have issued twelve-month target prices for Neurometrix's shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Neurometrix's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 136.2% from the stock's current price. View Analyst Ratings for Neurometrix.
What is the consensus analysts' recommendation for Neurometrix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Neurometrix's key competitors?
Some companies that are related to Neurometrix include Valeritas (VLRX), Presbia (LENS), Hancock Jaffe Laboratories (HJLI), Obalon Therapeutics (OBLN), Lianluo Smart (LLIT), AIT Therapeutics (AITB), Pro-Dex (PDEX), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Biostage (BSTG), DarioHealth (DRIO), Cytocore common stock (MDIT), STRATA Skin Sciences (SSKN), Alliqua Biomedical (ALQA) and United American Healthcare (UAHC).
Who are Neurometrix's key executives?
Neurometrix's management team includes the folowing people:
- Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 53)
- Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 66)
- Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 57)
- Mr. Richard J. Thomas, Pres
- Mr. Michael J. MacDonald, Sr. VP & GM of Diagnostics
Has Neurometrix been receiving favorable news coverage?
News stories about NURO stock have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurometrix earned a media sentiment score of 0.05 on Accern's scale. They also gave press coverage about the medical device company an impact score of 46.34 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Neurometrix?
Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurometrix's stock price today?
One share of NURO stock can currently be purchased for approximately $1.27.
How big of a company is Neurometrix?
Neurometrix has a market capitalization of $9.34 million and generates $17.09 million in revenue each year. Neurometrix employs 41 workers across the globe.
How can I contact Neurometrix?
Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]
MarketBeat Community Rating for Neurometrix (NASDAQ NURO)
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
